RCEL — AVITA Medical, Inc.

Summary of AVITA Medical, Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Reported revenue for Q3 2025 was approximately $17.1 million, down 13% year-over-year from $19.5 million in Q3 2024.
• Gross Margin: Gross profit margin decreased to 81.3% from 83.7% in the prior year, primarily due to product mix changes.
• Operating Expenses: Total operating expenses were $23 million, a 24% decrease from $30.2 million in Q3 2024, reflecting cost reduction initiatives.
• Net Loss: The net loss narrowed to $13.2 million or $0.46 per share, compared to $16.2 million or $0.62 per share in Q3 2024.
• Cash Position: Cash and equivalents increased to $23.3 million from $15.7 million at the start of the quarter, aided by a $13.8 million private placement.

2. Strategic Updates and Business Highlights

• The company is focusing on stabilizing reimbursement for its RECELL product following the introduction of new CPT codes, which has caused temporary disruptions.
• All 7 Medicare Administrative Contractors (MACs) have confirmed reimbursement rates, which is expected to restore clinician confidence and normalize demand.
• RECELL has been incorporated into treatment protocols at leading burn centers, highlighting its clinical validation.
• The company is refining its commercial organization to focus on the 200 burn centers and trauma hospitals that represent the majority of its revenue potential.
• Recent CE Mark approval for RECELL GO in Europe marks a significant milestone for international expansion.

3. Forward Guidance and Outlook

• Full-year revenue guidance has been revised to $70 million to $74 million, down from previous guidance of $76 million to $81 million due to slower-than-expected reimbursement normalization.
• The company expects to provide updated revenue guidance for 2026 in early Q1 2026, with a focus on returning to growth in RECELL utilization.

4. Bad News, Challenges, or Points of Concern

• The decline in revenue is attributed to ongoing reimbursement disruptions and the timing of hospital Value Analysis Committee (VAC) reviews.
• The company faces challenges in rebuilding clinician confidence in RECELL usage, which may take time despite the resolution of reimbursement issues.
• There is a risk that the normalization of demand may not occur as quickly as anticipated, affecting future revenue growth.
• The operating loss remains significant, although it has improved year-over-year.

5. Notable Q&A Insights

• Management emphasized the importance of educating providers on the new reimbursement processes to restore confidence and usage of RECELL.
• The focus remains primarily on the U.S. market, with limited resources allocated to international expansion to avoid distractions.
• There is optimism about the potential for revenue recovery as reimbursement clarity improves, but management cautioned that it will not be an immediate turnaround.
• Discussions on sales team restructuring indicate a shift toward aligning incentives with growth objectives, although specific changes are still under consideration.

Overall, while AVITA Medical has faced challenges in Q3 2025, particularly related to reimbursement issues, management is optimistic about future growth driven by improved reimbursement clarity and a focused commercial strategy.